1. Home
  2. KLRA vs NEO Comparison

KLRA vs NEO Comparison

Compare KLRA & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$14.84

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$17.66

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLRA
NEO
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
KLRA
NEO
Price
$14.84
$17.66
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.38
AVG Volume (30 Days)
719.9K
1.6M
Earning Date
N/A
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.63
Revenue Next Year
N/A
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.15
$7.07
52 Week High
$23.82
$19.76

Technical Indicators

Market Signals
Indicator
KLRA
NEO
Relative Strength Index (RSI) 36.75 61.84
Support Level N/A $15.72
Resistance Level $19.02 $19.76
Average True Range (ATR) 1.27 0.87
MACD -0.12 -0.06
Stochastic Oscillator 4.65 48.41

Price Performance

Historical Comparison
KLRA
NEO

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: